Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
Compare

CMRA vs. ARDS, TRVN, NAVB, SMFL, and AMPE

Should you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Aridis Pharmaceuticals (ARDS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Smart for Life (SMFL), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry.

How does Comera Life Sciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Comera Life Sciences Neutral

Comera Life Sciences has higher revenue and earnings than Aridis Pharmaceuticals. Comera Life Sciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Aridis Pharmaceuticals has a beta of 49.48, suggesting that its share price is 4,848% more volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Summary

Aridis Pharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Trevena?

Trevena (NASDAQ:TRVN) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Comera Life Sciences N/A N/A N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Comera Life Sciences Neutral

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Trevena has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Summary

Comera Life Sciences beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Comera Life Sciences Neutral

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Comera Life Sciences Neutral

Comera Life Sciences has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Smart for Life has a beta of 16.53, suggesting that its share price is 1,553% more volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Summary

Smart for Life beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Ampio Pharmaceuticals has a beta of 7.65, indicating that its share price is 665% more volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ampio Pharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Summary

Comera Life Sciences beats Ampio Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$889.47M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio0.001.7129.0428.47
Price / SalesN/A120.50476.6160.92
Price / CashN/A20.0727.6236.52
Price / BookN/A7.609.676.67
Net Income-$18M-$4.80M$3.55B$332.53M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/A0.0030
TRVN
Trevena
N/A$0.01
-44.5%		N/AN/A$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
SMFL
Smart for Life
N/A$0.00
flat		N/AN/A$8K$11.11MN/A110

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel